Related Experiment Video
Updated: May 29, 2025

04:23
A Swin Transformer-Based Model for Thyroid Nodule Detection in Ultrasound Images
Published on: April 21, 2023
1.7K
Detection of Alzheimer Disease in Neuroimages Using Vision Transformers: Systematic Review and Meta-Analysis
Vivens Mubonanyikuzo1, Hongjie Yan2, Temitope Emmanuel Komolafe3
1College of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Journal of Medical Internet Research
|February 5, 2025
Summary
Vision transformers (ViTs) show high accuracy in detecting Alzheimer disease (AD) from neuroimaging data. This systematic review confirms ViTs
Area of Science:
- Artificial Intelligence in Medicine
- Neuroimaging Analysis
- Deep Learning for Disease Diagnosis
Background:
- Alzheimer disease (AD) is a progressive neurodegenerative disorder causing cognitive decline.
- Vision transformers (ViTs) are advanced deep learning models with potential in medical image analysis.
- ViTs show promise for early detection and diagnosis of AD.
Purpose of the Study:
- Systematically review studies applying ViTs to AD detection.
- Evaluate the diagnostic accuracy of ViTs in AD.
- Assess the impact of network architecture on ViT performance for AD diagnosis.
Main Methods:
- Systematic literature search across major databases (PubMed, Web of Science, etc.) from 2020-2024.
- Included studies used ViT models with neuroimaging data (MRI, PET) for AD detection.
- Meta-analysis of diagnostic accuracy metrics (sensitivity, specificity, likelihood ratios) using random-effects models.
Main Results:
- Meta-analysis of 11 studies showed high pooled diagnostic accuracy for ViTs in AD detection.
- Sensitivity: 0.925, Specificity: 0.957, AUC: 0.924.
- ViTs demonstrate significant potential for accurate and early AD diagnosis.
Conclusions:
- ViT models are effective in distinguishing AD patients from healthy controls.
- This review supports ViTs as valuable tools for neuroimaging-based AD diagnostic methodologies.
- Findings offer insights for future advancements in AI-driven AD diagnostics.
Related Concept Videos
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Vision
52.9K
Vision is the result of light being detected and transduced into neural signals by the retina of the eye. This information is then further analyzed and interpreted by the brain. First, light enters the front of the eye and is focused by the cornea and lens onto the retina—a thin sheet of neural tissue lining the back of the eye. Because of refraction through the convex lens of the eye, images are projected onto the retina upside-down and reversed.
52.9K
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158

